Novartis

Propeller gets green light to bundle its digital health tools with inhalers
Propeller gets green light to bundle its digital health tools with inhalers
MedCity News
Novartis
Propeller Health
Europe
digital health
inhalers
digital therapeutics
Flag link:
Pharma's pandemic response could help attract tech talent, Novartis digital chief says
Pharma's pandemic response could help attract tech talent, Novartis digital chief says
Fierce Pharma
pharma industry
pandemic
COVID-19
Novartis
Flag link:
Novartis partners with Civica Rx to ease hospital shortages for 6 high-demand generic injectables
Novartis partners with Civica Rx to ease hospital shortages for 6 high-demand generic injectables
Fierce Pharma
Novartis
non-profits
Civica Rx
drug shortages
pandemic
COVID-19
Flag link:
Pfizer, Novartis and more halt July ads on Facebook to protest hate and racism
Pfizer, Novartis and more halt July ads on Facebook to protest hate and racism
Fierce Pharma
racism
pharma advertising
Pfizer
Novartis
AbbVie
Flag link:
Novartis to pay $678M to settle claims over 'sham' doctor events
Novartis to pay $678M to settle claims over 'sham' doctor events
BioPharma Dive
Novartis
physicians
legal
kickbacks
Flag link:
Amgen's Enbrel Patents to Be Upheld Through 2029
Amgen's Enbrel Patents to Be Upheld Through 2029
Motley Fool
psoriasis
rheumatoid arthritis
Enbrel
Novartis
biosimilars
patents
Flag link:
Novartis plots 2nd U.S. factory to meet demand for Lutathera and future cancer radiotherapies
Novartis plots 2nd U.S. factory to meet demand for Lutathera and future cancer radiotherapies
Fierce Pharma
Novartis
Lutathera
radiotherapy
drug manufacturing
Flag link:
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Endpoints
Takeda
Novartis
Xiidra
Europe
EMA
dry eye disease
Flag link:
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece
Fierce Pharma
Novartis
Greece
DOJ
Lucentis
kickbacks
physicians
Flag link:
Novartis strikes out with dry eye med Xiidra in Europe
Novartis strikes out with dry eye med Xiidra in Europe
Seeking Alpha
Novartis
dry eye disease
Europe
Xiidra
CHMP
Flag link:
Novartis inks settlements worth $347M with DOJ, SEC over foreign doctor payments, records keeping
Novartis inks settlements worth $347M with DOJ, SEC over foreign doctor payments, records keeping
Fierce Pharma
Novartis
DOJ
kickbacks
physicians
FCPA
SEC
Flag link:
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
Flag link:
Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial
Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial
Motley Fool
Novartis
clinical trials
hydroxychloroquine
COVID-19
pandemic
Flag link:
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis
Pharmaceutical Business Review
Novartis
Cosentyx
non-radiographic axial spondyloarthritis
Flag link:
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis
Fierce Pharma
Novartis
Eli Lilly
Cosentyx
Taltz
spondyloarthritis
Flag link:
UCB’s growth driver squares up against the competition
UCB’s growth driver squares up against the competition
EP Vantage
UCB Pharma
bimekizumab
psoriasis
clinical trials
Novartis
Cosentyx
Flag link:
FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
BioSpace
Novartis
Arzerra
FDA
ofatumumab
relapsing multiple sclerosis
Flag link:
Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis
Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis
Fierce Pharma
Eli Lilly
Taltz
Novartis
Cosentyx
axial spondyloarthritis
Flag link:
Big gene therapy names line up behind experimental Covid-19 vaccine
Big gene therapy names line up behind experimental Covid-19 vaccine
Stat
COVID-19
gene therapy
Novartis
AveXis
Flag link:
Novartis builds case for MS drug ofatumumab as FDA decision looms
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Flag link:

Pages